Literature DB >> 33528004

Attenuating Treatment-Related Cardiotoxicity in Women Recently Diagnosed With Breast Cancer via a Tailored Therapeutic Exercise Program: Protocol of the ATOPE Trial.

Paula Postigo-Martin1,2,3, Rafael Peñafiel-Burkhardt4, Tania Gallart-Aragón5, Miriam Alcaide-Lucena5, Francisco Artacho-Cordón3,6, Noelia Galiano-Castillo1,2,3,7, Carolina Fernández-Lao1,2,3,7, Lydia Martín-Martín1,2,3,7, Mario Lozano-Lozano1,2,3,7, Julia Ruíz-Vozmediano8, Salvador Moreno-Gutiérrez9, Rebeca Illescas-Montes10, Manuel Arroyo-Morales1,2,3,7, Irene Cantarero-Villanueva1,2,3,7.   

Abstract

OBJECTIVE: Therapeutic exercise is already used to ameliorate some of the side effects of cancer treatment. Recent studies examined its preventive potential regarding treatment-related toxicity, which can increase the risk of functional decline and lead to disease recurrence and death. This trial will examine whether the Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program, performed before treatment, can mitigate the onset and extent of cardiotoxicity beyond that achieved when the program is followed during treatment in recently diagnosed breast cancer patients.
METHODS: The intervention has a preparatory phase plus 12 to 18 sessions of tailored, high-intensity exercise, and post-exercise recovery strategies. A total of 120 women recently diagnosed with breast cancer, at risk of cardiotoxicity due to anticancer treatment awaiting surgery followed by chemotherapy and/or radiotherapy, will be randomized to either group. In a feasibility study, measurements related to recruitment rate, satisfaction with the program, adherence to them, the retention of participants, safety, and adverse effects will be explored. In the main trial, the efficacy of these interventions will be examined. The major outcome will be cardiotoxicity, assessed echocardiographically via the left ventricular ejection fraction. Other clinical, physical, and anthropometric outcomes and biological and hormonal variables will also be assessed after diagnosis, after treatment, 1 year after treatment ends, and 3 years after treatment ends.
CONCLUSION: Given its potential effect on patient survival, the mitigation of cardiotoxicity is a priority, and physical therapists have an important role in this mitigation. If the ATOPE intervention performed before treatment returns better cardioprotection results, it may be recommendable that patients recently diagnosed follow this program. IMPACT: The ATOPE program will highlight the need for a physical therapist intervention from the moment of diagnosis, in the prevention or mitigation of cardiotoxicity, in women with breast cancer. It could help physical therapists to establish an adequate therapeutic exercise dose adapted to breast cancer patients and to propose correct therapeutic exercise prescription according to the assimilation of the sessions.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Physical Therapy Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Breast Neoplasms; Cardiotoxicity; Mobile Application; Physical Therapy; Prehabilitation; Recovery Strategies; Therapeutic Exercise

Mesh:

Substances:

Year:  2021        PMID: 33528004     DOI: 10.1093/ptj/pzab014

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  2 in total

Review 1.  Novel Therapeutics for Anthracycline Induced Cardiotoxicity.

Authors:  Jacqueline T Vuong; Ashley F Stein-Merlob; Richard K Cheng; Eric H Yang
Journal:  Front Cardiovasc Med       Date:  2022-04-22

2.  mHealth system (ATOPE+) to support exercise prescription in breast cancer survivors: a reliability and validity, cross-sectional observational study (ATOPE study).

Authors:  Paula Postigo-Martin; Rocío Gil-Gutiérrez; Salvador Moreno-Gutiérrez; Maria Lopez-Garzon; Ángela González-Santos; Manuel Arroyo-Morales; Irene Cantarero-Villanueva
Journal:  Sci Rep       Date:  2022-09-08       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.